MORF - Morphic Holding Inc Stock Price, Fair Value and News

27.67USD-0.30 (-1.07%)Delayed as of 30 Apr 2024, 02:04 pm ET

Market Summary

USD27.67-0.30

Delayedas of 30 Apr 2024, 02:04 pm

-1.07%

MORF Stock Price

View Fullscreen

MORF RSI Chart

MORF Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-8.72

Price/Sales (Trailing)

2.7K

EV/EBITDA

-8.52

Price/Free Cashflow

-10.93

MORF Price/Sales (Trailing)

MORF Profitability

EBT Margin

-30868.71%

Return on Equity

-24.3%

Return on Assets

-23.62%

Free Cashflow Yield

-9.15%

MORF Fundamentals

MORF Revenue

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

MORF Earnings

Earnings (TTM)

-161.3M

Earnings Growth (Yr)

-25.35%

Earnings Growth (Qtr)

-11.19%

Breaking Down MORF Revenue

52 Week Range

19.8063.08

(Low)(High)

Last 7 days

-1.9%

Last 30 days

-20.5%

Last 90 days

-9.9%

Trailing 12 Months

-40.8%

How does MORF drawdown profile look like?

MORF Financial Health

Current Ratio

38.17

MORF Investor Care

Shares Dilution (1Y)

26.21%

Diluted EPS (TTM)

-3.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	53.2M	35.7M	18.1M	521.0K
2022	32.5M	45.3M	58.1M	70.8M
2021	42.6M	38.8M	16.1M	19.8M
2020	24.0M	31.0M	38.0M	44.9M
2019	9.1M	14.9M	20.7M	17.0M
2018	0	0	0	3.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Morphic Holding Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 27, 2024	rogers bruce	acquired	31,931	4.3151	7,400	president
Jan 16, 2024	rogers bruce	sold	-173,576	27.4907	-6,314	president
Jan 16, 2024	schegerin marc	sold	-166,071	27.4907	-6,041	cfo and coo
Jan 16, 2024	farrell robert e jr	sold	-139,900	27.4907	-5,089	svp finance and cao
Jan 16, 2024	tipirneni praveen p.	sold	-382,753	27.4907	-13,923	ceo
Jan 16, 2024	devaul william	sold	-123,956	27.4907	-4,509	general counsel and secretary
Jan 14, 2024	rogers bruce	acquired	-	-	5,070	president
Jan 14, 2024	tipirneni praveen p.	acquired	-	-	12,500	ceo
Jan 14, 2024	schegerin marc	acquired	-	-	4,690	cfo and coo
Jan 14, 2024	devaul william	acquired	-	-	3,250	general counsel and secretary

Which funds bought or sold MORF recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Allworth Financial LP	unchanged	-	101	564	-%
Apr 25, 2024	HealthInvest Partners AB	unchanged	-	94,496	526,310	0.32%
Apr 25, 2024	nVerses Capital, LLC	new	-	38,720	38,720	0.09%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-3.66	652,322	4,396,270	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	1,718	114,000	119,000	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	unchanged	-	28,977	161,392	-%
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	581	3,238	-%
Apr 24, 2024	Assenagon Asset Management S.A.	reduced	-26.73	-300,830	2,512,720	0.01%
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	62,000	441,000	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-75.38	-103,000	44,000	-%

Are Funds Buying or Selling MORF?

Are funds buying MORF calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MORF

No. of Funds

Unveiling Morphic Holding Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ecor1 capital, llc	0.4%	211,262	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	9.2%	4,591,000	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	0.4%	211,262	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	polaris partners vii, l.p.	3.7%	1,860,498	SC 13G/A
Feb 09, 2024	artal international s.c.a.	4.3%	2,138,188	SC 13G/A
Feb 08, 2024	wellington management group llp	6.79%	3,377,310	SC 13G
Jan 26, 2024	blackrock inc.	6.6%	3,302,686	SC 13G/A
Jan 24, 2024	state street corp	5.15%	2,564,058	SC 13G
Oct 18, 2023	springer timothy a	15.8%	7,577,651	SC 13D

Recent SEC filings of Morphic Holding Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	424B5	Prospectus Filed
Apr 26, 2024	8-K	Current Report
Apr 26, 2024	S-3ASR	S-3ASR
Apr 25, 2024	10-Q	Quarterly Report
Apr 25, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Mar 28, 2024	4	Insider Trading
Mar 19, 2024	3	Insider Trading

Peers (Alternatives to Morphic Holding Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Morphic Holding Inc News

Latest updates

Morphic Holding Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-	-	-	1,533,750	3,067,500	4,601,250	6,135,000	2,055,000	60,236,000	34,896,250	9,556,500	3,124,000	3,848,000	3,265,000	5,901,000	25,757,000	7,693,000	5,594,000	5,634,500	5,675,000	5,567,000	6,068,000
Costs and Expenses	8.4%	53,604,000	49,431,000	44,748,000	45,302,000	39,726,000	32,716,000	33,548,000	33,886,000	34,054,000	31,101,500	28,242,000	31,691,000	24,566,000	23,880,000	20,749,000	24,113,000	23,383,000	20,246,000	15,533,000	15,984,000	12,202,000
S&GA Expenses	-100.0%	-	9,579,000	10,384,000	9,583,000	9,277,000	8,014,000	8,303,000	8,234,000	7,591,000	7,443,500	7,276,000	7,139,000	5,953,000	5,126,500	4,751,000	4,195,000	4,423,000	3,426,000	2,898,000	2,077,000	1,832,000
R&D Expenses	6.5%	42,441,000	39,852,000	34,364,000	35,719,000	30,449,000	24,702,000	25,245,000	25,652,000	26,463,000	23,658,000	20,966,000	24,552,000	18,613,000	18,753,500	15,998,000	19,918,000	18,960,000	16,820,000	12,635,000	13,907,000	10,370,000
EBITDA Margin	-6.0%	-306	-289	-7.43	-3.60	-1.18	-0.82	-0.95	-1.10	-3.22	-4.77	-5.64	-1.57	-1.15	-	-	-	-	-	-	-	-
Income Taxes	-37.0%	80,000	127,000	83,000	138,000	32,000	36,000	29,000	2,000	-	-	-	-	-	-143,000	-115,000	-155,000	-157,000	344,000	304,000	135,000	129,000
Earnings Before Taxes	-11.3%	-45,214,000	-40,608,000	-36,129,000	-38,875,000	-36,103,000	-24,341,000	-29,992,000	26,843,000	-31,484,000	-21,402,000	-25,041,000	-27,815,000	-21,284,000	-17,892,000	5,239,000	-16,013,000	-16,903,000	-19,487,500	-8,560,000	-9,298,000	-5,071,000
EBT Margin	-6.0%	-308	-291	-7.49	-3.63	-1.19	-0.83	-0.97	-1.13	-3.25	-4.83	-5.70	-1.59	-1.17	-	-	-	-	-	-	-	-
Net Income	-11.2%	-45,294,000	-40,735,000	-36,212,000	-39,013,000	-36,135,000	-24,377,000	-30,021,000	26,841,000	-31,484,000	-21,402,000	-25,041,000	-27,815,000	-21,284,000	-17,749,000	5,354,000	-15,858,000	-16,746,000	-19,831,000	-8,864,000	-9,433,000	-5,200,000
Net Income Margin	-6.0%	-309	-291	-7.50	-3.63	-1.20	-0.83	-0.97	-1.13	-3.25	-4.83	-5.69	-1.59	-1.16	-	-	-	-	-	-	-	-
Free Cashflow	-64.2%	-47,063,000	-28,667,000	-29,555,000	-23,327,000	-32,004,000	-25,182,000	-25,143,000	-22,821,000	-28,196,000	-21,042,000	-24,936,000	-18,062,000	-20,441,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-5.5%	683	723	744	749	442	369	389	414	397	426	439	439	460	242	222	212	229	247	260	179	189
Current Assets	-5.7%	676	717	738	743	436	362	382	407	389	418	435	437	457	239	218	209	226	244	257	173	187
Cash Equivalents	-23.1%	45.00	59.00	74.00	217	42.00	59.00	85.00	141	120	171	184	399	396	102	98.00	133	107	102	160	44.00	186
Net PPE	-0.6%	3.00	3.00	2.00	3.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00
Liabilities	-24.7%	19.00	25.00	20.00	19.00	15.00	19.00	24.00	26.00	84.00	90.00	88.00	92.00	91.00	97.00	91.00	97.00	101	107	101	105	102
Current Liabilities	-28.5%	18.00	25.00	19.00	18.00	13.00	17.00	19.00	20.00	44.00	38.00	42.00	35.00	34.00	39.00	36.00	45.00	37.00	35.00	26.00	44.00	35.00
Shareholder's Equity	-4.8%	664	697	723	729	427	349	365	388	313	337	350	348	369	145	130	115	128	141	159	-	-
Retained Earnings	-10.1%	-494	-449	-408	-372	-333	-297	-272	-242	-269	-238	-216	-191	-163	-142	-124	-130	-114	-97.51	-77.68	-68.82	-54.18
Additional Paid-In Capital	1.3%	1,158	1,144	1,133	1,104	761	650	642	633	585	575	567	540	533	288	255	245	242	238	237	3.00	2.00
Shares Outstanding	0.7%	50.00	50.00	50.00	48.00	40.00	39.00	38.00	38.00	37.00	36.00	35.00	35.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,140	-	-	-	559	-	-	-	1,018	-	-	-	318	-	-	-	374	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-62.3%	-46,389	-28,574	-29,250	-23,034	-31,454	-25,118	-24,894	-22,817	-28,148	-20,585	-24,578	-17,908	-20,390	-14,418	3,731	-16,360	-18,943	-14,075	-13,696	-14,068	188
Share Based Compensation	27.2%	13,375	10,518	10,534	10,315	9,576	7,123	7,537	7,623	6,765	5,643	5,791	5,308	4,442	3,024	2,996	2,489	2,544	1,377	989	667	499
Cashflow From Investing	143.4%	31,367	12,885	-133,082	-133,217	-88,401	-1,146	-32,509	3,278	-26,074	5,186	-211,961	19,846	73,749	-11,295	-46,051	41,911	23,616	-44,201	34,204	17,681	-143,670
Cashflow From Financing	2579.4%	911	34.00	19,288	331,626	102,484	575	1,181	40,880	2,630	2,674	21,579	1,481	240,579	29,680	7,279	535	803	28.00	95,100	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MORF Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 0	$ 521
Operating expenses:
Research and development	42,441	30,449
General and administrative	11,163	9,277
Total operating expenses	53,604	39,726
Loss from operations	(53,604)	(39,205)
Other income:
Interest income, net	8,390	3,100
Other income, net	0	2
Total other income, net	8,390	3,102
Loss before provision for income taxes	(45,214)	(36,103)
Provision for income taxes	(80)	(32)
Net loss	$ (45,294)	$ (36,135)
Net loss per share, basic (in dollars per share)	$ (0.91)	$ (0.90)
Net loss per share, diluted (in dollars per share)	$ (0.91)	$ (0.90)
Weighted average common shares outstanding, basic (in shares)	50,009,032	40,112,416
Weighted average common shares outstanding, diluted (in shares)	50,009,032	40,112,416
Comprehensive loss:
Net loss	$ (45,294)	$ (36,135)
Other comprehensive (loss) income :
Unrealized holding (losses) gains on marketable securities, net of tax	(2,519)	1,651
Total other comprehensive (loss) income	(2,519)	1,651
Comprehensive loss	$ (47,813)	$ (34,484)

MORF Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 44,410	$ 58,577
Marketable securities	614,356	645,772
Prepaid expenses and other current assets	17,175	12,579
Total current assets	675,941	716,928
Operating lease right-of-use assets	3,101	2,133
Property and equipment, net	2,750	2,767
Restricted cash	616	560
Other assets	357	126
Total assets	682,765	722,514
Current liabilities:
Accounts payable	5,748	7,698
Accrued expenses	11,963	17,078
Total current liabilities	17,711	24,776
Long-term liabilities:
Operating lease liability, net of current portion	1,474	716
Total liabilities	19,185	25,492
Commitments and contingencies (Note 9)
Stockholders’ Equity
Preferred shares, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common shares, $0.0001 par value, 400,000,000 shares authorized, 50,093,588 shares issued and outstanding as of March 31, 2024 and 49,747,286 shares issued and outstanding as of December 31, 2023	5	5
Additional paid‑in capital	1,158,290	1,143,919
Accumulated deficit	(494,484)	(449,190)
Accumulated other comprehensive (loss) income	(231)	2,288
Total stockholders’ equity	663,580	697,022
Total liabilities and stockholders’ equity	$ 682,765	$ 722,514

About Morphic Holding Inc

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ÃƒÅ¸7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ÃƒÅ¸7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avÃƒÅ¸8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with SchrÃƒÂ¶dinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CEO	Dr. Praveen P. Tipirneni M.D.
WEBSITE	morphictx.com
INDUSTRY	Biotechnology
EMPLOYEES	110

Morphic Holding Inc Frequently Asked Questions

What is the ticker symbol for Morphic Holding Inc? What does MORF stand for in stocks?

MORF is the stock ticker symbol of Morphic Holding Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Morphic Holding Inc (MORF)?

As of Tue Apr 30 2024, market cap of Morphic Holding Inc is 1.41 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MORF stock?

You can check MORF's fair value in chart for subscribers.

What is the fair value of MORF stock?

You can check MORF's fair value in chart for subscribers. The fair value of Morphic Holding Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Morphic Holding Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MORF so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Morphic Holding Inc a good stock to buy?

The fair value guage provides a quick view whether MORF is over valued or under valued. Whether Morphic Holding Inc is cheap or expensive depends on the assumptions which impact Morphic Holding Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MORF.

What is Morphic Holding Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, MORF's PE ratio (Price to Earnings) is -8.72 and Price to Sales (PS) ratio is 2.7 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MORF PE ratio will change depending on the future growth rate expectations of investors.